Delcath Systems (DCTH) is an interventional oncology company focused on the treatment of primary and metastatic liver cancers.
Employees: 11-50
Total raised: $33.8M
Founded date: 1988
Investors 1
| Date | Name | Website |
| - | Centrecour... | centrecour... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 26.08.2010 | - | $33.8M | - |
Mentions in press and media 15
| Date | Title | Description |
| 07.05.2024 | Delcath Systems to Host First Quarter 2024 Earnings Call | QUEENSBURY, N.Y., May 7, 2024 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a conference call o... |
| 30.03.2023 | Delcath Systems Announces Closing of Private Placement of up to $85 Million | Led by Vivo Capital with participation from Logos Capital, BVF Partners LP, Stonepine Capital Management, LLC, Serrado Capital LLC and supported by existing investor, Rosalind Advisors $25 million financing upfront with up to an additional ... |
| 28.03.2023 | Delcath Systems To Raise Up To $85M Financing | Delcath Systems, Inc. (Nasdaq: DCTH), a NYC-based interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, signed securities purchase agreements with certain healthcare-focused institutional i... |
| 04.10.2022 | ROTH Capital Partners to Host Inaugural Healthcare Opportunities Conference on October 6th at the Yale Club in New York City | Event to feature company presentations and one-on-one meetings between institutional investors and senior management from select Healthcare companies in Biotechnology, Pharmaceuticals, Medical Technologies, Oncology and Mental Health Therap... |
| 09.08.2021 | Delcath Systems Secures Up to a $20.0 Million Debt Facility with Avenue Venture Opportunities Fund, L.P. | NEW YORK, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, announced today that it has entered into a de... |
| 09.08.2021 | Delcath Systems Secures Up to A $20.0 Million Debt Facility with Avenue Venture Opportunities Fund, L.P | Delcath Systems, Inc. announced that it has entered into a debt facility with Avenue Venture Opportunities Fund, L.P. ("Avenue Venture Fund") providing up to $20 million with an initial $15 million funded at close. Additional deta... |
| 19.12.2014 | Delcath expands Phase II trial | Delcath Systems (NSDQ:DCTH) said it added 2 German research centers to a global Phase II trial of its Chemosat melphalan hepatic delivery system in treating primary liver cancer. The 2 facilities, Hannover Medical School Hospital and Jena U... |
| 23.10.2013 | Troubled Delcath announces $7.5M offering, drops 23% | New York’s Delcath Systems (NSDQ:DCTH) is looking to raise about $7.5 million through sales of common stock, planning on using the funds for working capital, commercialization efforts, clinical trials and other "general corporate purpo... |
| 03.05.2013 | Delcath plunges after FDA panel recommends against liver cancer treatment approval | Shares of Delcath (NSDQ:DCTH) have lost nearly half their value so far today after an FDA panel recommended against approval for its liver cancer treatment. The FDA’s Oncologic Drugs Advisory Committee voted 16-0 that the risks associated w... |
| 04.02.2013 | German reimbursement win sends Delcath shares up 8% | Delcath (NSDQ:DCTH) shares gained 8% today after the German government decided to reimburse patients who receive the medical device company’s Chemosat liver cancer treatment. The German federal reimbursement agency, the Institut für das Ent... |
Show more